LENZ Therapeutics’ Post

 In recognition of National Glaucoma Awareness Month, we would like to continue to spotlight our portfolio companies working towards better treatments of Glaucoma. At OIS XIII, CEO David Esposito discussed ONL’s lead compound, ONL1204, and its promise across various eye indications. In geographic atrophy (GA), a single injection demonstrated a 42% slowing of lesion growth over six months. In open-angle glaucoma, ONL1204 indicated structural and functional improvement in under 12 months. ONL Therapeutics aims to provide IOP-independent neuroprotection for glaucoma. They plan to report topline results for retinal detachment in April-May, progress to a registrational study for GA in 2024, and explore neuroenhancement in glaucoma with a potential Phase 2 study in 2025. Watch the full video below: #glaucomaawareness #glaucomaawarenessmonth #investintheeye #ophthalmology https://lnkd.in/eHziCgaV

Overview The report assesses global trends in R&D activity, focusing on new drug launches, clinical trial initiations, R&D funding, and productivity enablers. It highlights the resilience and adaptability of the R&D ecosystem post-COVID-19, emphasizing the continued high value placed on innovative therapeutic research. R&D Funding 2023 Rebound: Biopharma funding rebounded to $72 billion, up from $61 billion in 2022, although still below the pandemic peak levels. M&A Activity: Merger and acquisition (M&A) activity surged to $140 billion from $78 billion in 2022, with notable deals in antibody drug conjugates (ADCs) and oncology. Pharma R&D Expenditure: Large pharma companies reported a record $161 billion in R&D spending, marking a 50% increase since 2018 and representing 23.4% of net sales. Clinical Trial Activity Decline in Trial Starts: Trial starts decreased by 15% in 2023 compared to the previous year and were down 22% from 2021, primarily due to fewer COVID-19-related trials. Disease Focus: The top four disease areas—oncology, immunology, metabolic/endocrinology, and neurology—accounted for 79% of trial starts. Oncology remained the dominant focus. Geographic Shifts: The share of trial starts from China-headquartered companies increased significantly, reflecting the growing influence of Chinese biopharma in global R&D. New Drug Approvals and Launches Increase in NAS Launches: A total of 69 novel active substances (NASs) were launched globally in 2023, a return to pre-COVID-19 trends. The U.S. led with the highest number of NAS launches, followed by the EU4+UK and China. First-in-Class Innovations: Significant first-in-class launches included cell and gene therapies in oncology and treatments for menopause and neurology. Clinical Development Productivity Improved Success Rates: Productivity in clinical development increased due to higher success rates, which rose to 10.8% in 2023 from a low of 5.9% in 2022. Complexity and Duration: Trial complexity saw mixed results, with some reduction in the number of countries and sites involved in rare diseases and oncology trials. However, overall development timelines increased due to longer "white space" periods between trial phases. Productivity Enablers Regulatory Adaptations: Regulatory agencies worldwide are enhancing transparency, flexibility, and speed, although capacity constraints are delaying consistent implementation in some regions. Innovative Trial Designs: Use of predictive biomarkers, real-world evidence, single-arm trials, and combined phases are contributing to shorter development durations. AI and Advanced Analytics: There was a significant rise in deals involving AI, machine learning, and advanced analytics, reflecting their growing role in drug discovery and clinical trial optimization. #pharma #pharmatrends #pharmaoverview #pharmadevelopment #pharmamarket #R&D #pharmalaunches #newdrugsapproval #clinicaltrials #globalmarketinsights

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine A Value-added Stable Presentation where NO Reconstitution, Dilution or Refrigeration requires. https://lnkd.in/gzrGv2Q6 #Amneal #PEMRYDI_RTU

The #celltherapy world is trying to master manufacturing processes which biologically are unbelievably complex. The delay by the FDA due to resource issues for Iovance Biotherapeutics, Inc. #melanoma #TIL therapy is of course frustrating for investors, but what about the impact for patients who haven't responded to conventional treatments? How can #cellandgenetherapy companies better prepare to navigate the regulatory maze and minimize delays in the approval of new therapies to allow better and wider patient access? #futureofhealthcare #futureofmedicine

Click here for the full content: https://bit.ly/CT-765975 On Monday, August 7, #Poseida and #Astellas announced (press release: https://bit.ly/45kSkNN) a strategic investment to support the advancement of Poseida’s #celltherapy assets in solid tumors with Astellas receiving the right of exclusive negotiation and first refusal to license P-MUC1C-ALLO1 (allogeneic #MUC1C CAR-T). Additionally, Poseida provided (press release: https://bit.ly/47DBQTd) a business update on its allogeneic CAR-T programs and #Gracell reported (press release: https://bit.ly/3DRfK1Q) up to $150M in private placement financing by a syndicate of premier healthcare investors. Celltelligence provides insights on Astellas’s interest in allogeneic cell therapies, while discussing how Poseida and Gracell could benefit from these investments.

GPCR Therapeutics is thrilled to announce a significant out-licensing agreement with Bridge Biotherapeutics, Inc. focused on the development and commercialization of a combination therapy involving our CXCR4-LPA1 inhibitor method, to aid our pursuit of innovative treatments for Idiopathic Pulmonary #Fibrosis (IPF). The scientific basis for this approach was recently published in the peer-reviewed journal 'Cell Communication and Signalling,' (https://lnkd.in/exTvdTxP) highlighting the potential of this innovative treatment for fibrotic diseases like IPF. We are excited about the prospects this collaboration brings and the opportunity to explore new avenues in IPF treatment alongside Bridge Biotherapeutics. IPF is a chronic lung condition causing scarring, making breathing progressively difficult. With no current treatment to halt or reverse scarring, our joint efforts aim to revolutionize IPF treatment and improve outcomes for patients. 📝 Read our press release: http://gpcr.co.kr/news/ 🔗 Learn more about our platform technology: https://lnkd.in/eH8YveC8 #BioTech #LungDisease #LungHealth

We are excited to be attending Ottawa NMD 2023 (https://lnkd.in/ewqhua8c)! It has been a great meeting focusing on basic and clinical science. Amy Hicks from Entrada Therapeutics shares updates on our exon 45 skipping program for Duchenne Muscular Dystrophy. If you are at the conference and want to learn more, please stop by at poster #102!

An exclusive presentation on Day 2 of the 7th Alcor Drug Discovery Platform featuring Raphaël G. Ognar, MSc MBA, CEO & Founder of NKILT Therapeutics, Inc. Raphaël, also the Chairman for Day 2, will provide a comprehensive update on the development of the unique CIR™ (Chimeric ILT-Receptor) technology. Gain insights into the latest data in AML and solid tumors, with a special focus on allogeneic and off-the-shelf technologies aimed at broadening treatment options for more patients. Don't miss this opportunity to stay at the forefront of innovative therapies! #AlcorDrugDiscovery #ADDP2024 #Innovation #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits

Sharing an in-depth look at the “radiopharma” competitive landscape, courtesy of OPCO. Dive into the latest insights on this potentially impactful modality that is poised to change the standard of care in oncology! #biotech #healthcare #medicine #radiopharma #oncology #cancer

Get insights from the #Hematology experts at #ASH23. Join PVI, PeerView Institute for Medical Education for #MedEd live events on #MM, #MDS, #CLL, #AML, and #COVID19; and overviews of novel therapeutics in various disease settings. https://lnkd.in/er2rM6R9